Follicular Lymphoma

FDA to Review sBLA for Axi-Cel in R/R Follicular Lymphoma and Marginal Zone Lymphoma

September 05, 2020

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.

Doctors Debate: Should Asymptomatic Patients With Follicular Lymphoma Be Actively Monitored With Watch-and-Wait Strategy or Immediately Treated?

September 01, 2020

The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.

Lenalidomide/Rituximab Induction as Effective as Rituximab Plus Chemo in Follicular Lymphoma Subset

August 04, 2020

Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).

Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point

August 04, 2020

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

Tazemetostat Approval Addresses Unmet Need in Relapsed/Refractory Follicular Lymphoma

June 26, 2020

In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.

FDA Approves Tazemetostat for Relapsed/Refractory Follicular Lymphoma

June 18, 2020

"The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma."

Rolling NDA Submitted to FDA for Umbralisib as Treatment of Marginal Zone, Follicular Lymphomas

June 17, 2020

“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."